EphA2-targeted CAR-DC and CAR-T cell therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must be stage IV (spread to other parts of the body) and have at least one tumor that can be measured on a scan.
- A test on your tumor tissue must show it has a protein called EphA2 on at least 20% of cancer cells.
- You must have tried at least two earlier treatments (like chemotherapy or immunotherapy) and your cancer still grew, or no standard treatment is available.
- You need to be feeling well enough to do daily activities (ECOG score 0 or 1) and have a life expectancy of at least 6 months.
- You must have enough blood counts, healthy liver and kidney function, and no uncontrolled infections.
- You cannot have serious heart problems or other major health issues that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
This early-stage trial tests a special immune cell treatment (CAR T cells) designed to target and attack lung cancer cells that have a protein called CEA on their surface. It's for people with advanced lung cancer who have already tried at least two standard treatments without success.
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.